Rani Therapeutics Holdings, a clinical-stage biotherapeutics company, announced a registered direct offering of Class A common stock priced at-the-market under Nasdaq rules. The offering includes 12.48 million shares and pre-funded warrants for 6.21 million shares, priced around $1.07 each, led by a sovereign wealth fund and healthcare-focused investors. The gross proceeds are expected to be approximately $20 million, which will support Rani's development of its oral biologics delivery technology, including the RaniPill®. The offering is expected to close around May 27, 2026, subject to customary conditions.
Ether has surged about 11% over the past week, outperforming other major cryptocurrencies like Bitcoin, which rose 4%. This rise is driven by $96 million inflows into U.S. spot ether ETFs, mainly BlackRock’s low-fee funds, while Grayscale’s higher-fe...
Veea Inc. has announced the commercial release of VeeaONE, a full-stack AI infrastructure platform that integrates edge-to-cloud hardware and software. The platform supports VeeaWare middleware on NVIDIA Jetson and x86/Arm servers, enabling secure, l...
Virtuals Protocol has introduced customizable tokenized indexes on the Robinhood Chain, allowing users to combine multiple assets into a single token. This innovation enables users to create and manage their own asset baskets and earn fees when other...
US spot Bitcoin ETFs saw net inflows of $107.8 million on Wednesday, while Ethereum ETFs attracted $53.8 million, signaling renewed institutional interest in crypto funds. Since their launch in January 2024, Bitcoin ETFs have accumulated over $51 bil...
Kaia has signed a strategic partnership with Xilo Labs to integrate Mochi, an onchain asset management platform, into Kaia's ecosystem. This collaboration allows users to invest stablecoins into diversified portfolios backed by tokenized real-world a...
